β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats

Lipids Health Dis. 2012 Jan 13:11:11. doi: 10.1186/1476-511X-11-11.

Abstract

Background: There is increasing interest in non-pharmacological control of cholesterol and triglyceride levels in the plasma and diet-drug association represent an important area of studies. The objective of this study was to observe the hypocholesterolemic effect of soybean β-conglycinin (7S protein) alone and combined with fenofibrate and rosuvastatin, two hypolipidemic drugs.

Methods: The protein and drugs were administered orally once a day to rats and the effects were evaluated after 28 days. Wistar rats were divided into six groups (n = 9): hypercholesterolemic diet (HC), HC+7S protein (300 mg.kg-1 day-1) (HC-7S), HC+fenofibrate (30 mg.kg-1 day-1)(HC-FF), HC+rosuvastatin (10 mg.kg-1 day-1)(HC-RO), HC+7S+fenofibrate (HC-7S-FF) and HC+7S+rosuvastatin (HC-7S-RO).

Results: Animals in HC-7S, HC-FF and HC-RO exhibited reductions of 22.9, 35.8 and 18.8% in total plasma cholesterol, respectively. In HC-7S-FF, animals did not show significant alteration of the level in HC+FF while the group HC-7S-RO showed a negative effect in comparison with groups taking only protein (HC-7S) or drug (HC-RO). The administration of the protein, fenofibrate and rosuvastatin alone caused increases in the plasma HDL-C of the animals, while the protein-drug combinations led to an increase compared to HC-FF and HC-RO. The plasma concentration of triacylgycerides was significantly reduced in the groups without association, while HC-7S-FF showed no alteration and HC-7S-RO a little reduction.

Conclusion: The results of our study indicate that conglycinin has effects comparable to fenofibrate and rosuvastatin on the control of plasma cholesterol, HDL-C and triacylglycerides, when given to hypercholesterolemic rats, and suggests that the association of this protein with rosuvastatin alters the action of drug in the homeostasis of cholesterol.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticholesteremic Agents / isolation & purification
  • Anticholesteremic Agents / pharmacology*
  • Anticholesteremic Agents / therapeutic use
  • Antigens, Plant / isolation & purification
  • Antigens, Plant / pharmacology*
  • Antigens, Plant / therapeutic use
  • Cholesterol / blood
  • Cholesterol / metabolism
  • Diet, High-Fat / adverse effects
  • Dietary Proteins / isolation & purification
  • Dietary Proteins / pharmacology*
  • Dietary Proteins / therapeutic use
  • Drug Combinations
  • Drug Synergism
  • Fenofibrate / pharmacology*
  • Fenofibrate / therapeutic use
  • Fluorobenzenes / pharmacology*
  • Fluorobenzenes / therapeutic use
  • Globulins / isolation & purification
  • Globulins / pharmacology*
  • Globulins / therapeutic use
  • Glycine max*
  • Heart / drug effects
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / drug therapy
  • Hypercholesterolemia / etiology
  • Liver / drug effects
  • Liver / metabolism
  • Liver / pathology
  • Male
  • Myocardium / pathology
  • Organ Size / drug effects
  • Pyrimidines / pharmacology*
  • Pyrimidines / therapeutic use
  • Rats
  • Rats, Wistar
  • Rosuvastatin Calcium
  • Seed Storage Proteins / isolation & purification
  • Seed Storage Proteins / pharmacology*
  • Seed Storage Proteins / therapeutic use
  • Soybean Proteins / isolation & purification
  • Soybean Proteins / pharmacology*
  • Soybean Proteins / therapeutic use
  • Sulfonamides / pharmacology*
  • Sulfonamides / therapeutic use
  • Triglycerides / blood
  • Triglycerides / metabolism

Substances

  • Anticholesteremic Agents
  • Antigens, Plant
  • Dietary Proteins
  • Drug Combinations
  • Fluorobenzenes
  • Globulins
  • Pyrimidines
  • Seed Storage Proteins
  • Soybean Proteins
  • Sulfonamides
  • Triglycerides
  • beta-conglycinin protein, Glycine max
  • Rosuvastatin Calcium
  • Cholesterol
  • Fenofibrate